UT Health McGovern School of Medicine, Houston, Texas, USA.
Department of Neurology, Institute for Stroke and Cerebrovascular Disease, UT Health McGovern School of Medicine, Houston, TX.
J Neurointerv Surg. 2019 Apr;11(4):367-372. doi: 10.1136/neurintsurg-2018-014112. Epub 2018 Sep 5.
The likelihood of retreatment in patients undergoing procedures for cerebral aneurysms (CAs) has an important role in deciding the optimal treatment type. Existing determinations of retreatment rates, particularly for unruptured CAs, may not represent current clinical practice.
To use population-level data to examine a large cohort of patients with treated CAs over a 10-year period to estimate retreatment rates for both ruptured and unruptured CAs and explore the effect of changing treatment practices.
We used administrative data from all non-federal hospitalizations in California (2005-2011) and Florida (2005-2014) and identified patients with treated CAs. Surgical clipping (SC) and endovascular treatments (ETs) were defined by corresponding procedure codes and an accompanying code for ruptured or unruptured CA. Retreatment was defined as subsequent SC or ET.
Among 19 482 patients with treated CAs, ET was performed in 12 007 (62%) patients and SC in 7475 (38%). 9279 (48%) patients underwent treatment for unruptured CAs and 10203 (52%) for ruptured. Retreatment after 90 days occurred in 1624 (8.3%) patients (11.2% vs 3.7%, ET vs SC). Retreatment rates for SC were greater in unruptured than in ruptured aneurysms (4.6% vs 3.1%), but the opposite was true for ET (10.6% vs 11.8%). 85% of retreatments were within 2 years of the index treatment. Retreatment was associated with age (OR=0.99, 95% CI 0.98 to 0.99), female sex (OR=1.5, 95% CI 1.3 to 1.7), Hispanic versus white race (OR=0.86, 95% CI 0.75 to 0.98), and ET versus SC (OR=3.25, 95% CI 2.85 to 3.71). The adjusted 2-year retreatment rate decreased from 2005 to 2012 for patients with unruptured CAs treated with ET (11% to 8%).
Retreatment rates for CAs treated with ET were greater than those for SC. However, for patients with unruptured CAs treated with ET, we identify a continuous decline in retreatment rate over the past decade.
在接受脑动脉瘤(CA)治疗的患者中,再次治疗的可能性在决定最佳治疗类型方面起着重要作用。现有复发性率的确定,特别是未破裂 CA 的复发性率,可能无法代表当前的临床实践。
利用人群数据,对 10 年间接受治疗的大量 CA 患者进行检查,以估算破裂和未破裂 CA 的再次治疗率,并探讨治疗实践变化的影响。
我们使用了加利福尼亚州(2005-2011 年)和佛罗里达州(2005-2014 年)所有非联邦医院的行政数据,确定了接受治疗的 CA 患者。手术夹闭(SC)和血管内治疗(ET)通过相应的程序代码和破裂或未破裂 CA 的伴随代码来定义。再次治疗定义为随后的 SC 或 ET。
在 19482 名接受治疗的 CA 患者中,12007 名(62%)患者接受了 ET,7475 名(38%)患者接受了 SC。9279 名(48%)患者接受了未破裂 CA 的治疗,10203 名(52%)患者接受了破裂 CA 的治疗。90 天后再次治疗的患者有 1624 名(8.3%)(ET 为 11.2%,SC 为 3.7%)。未破裂动脉瘤的 SC 再治疗率高于破裂动脉瘤(4.6% vs 3.1%),但 ET 则相反(10.6% vs 11.8%)。85%的再次治疗发生在指数治疗后 2 年内。再次治疗与年龄(OR=0.99,95%CI 0.98 至 0.99)、女性(OR=1.5,95%CI 1.3 至 1.7)、西班牙裔与白人种族(OR=0.86,95%CI 0.75 至 0.98)以及 ET 与 SC(OR=3.25,95%CI 2.85 至 3.71)相关。未破裂 ET 治疗的 CA 患者的 2 年调整后再治疗率从 2005 年到 2012 年下降(11%至 8%)。
接受 ET 治疗的 CA 患者的再治疗率高于 SC。然而,对于接受 ET 治疗的未破裂 CA 患者,我们发现过去十年中再治疗率持续下降。